UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
(Mark One)
For
the quarterly period ended
OR
For the transition period from __________ to __________
Commission
File Number:
(Exact Name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large Accelerated filer | ☐ | Accelerated filer | ☐ | |||
| ☒ | Smaller reporting company | |||||
| Emerging growth company |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
As
of August 14, 2023, the registrant had
Table of Contents
i
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited).
INTENSITY THERAPEUTICS, INC.
Condensed Balance Sheets
(Unaudited)
| June
30, 2023 | December
31, 2022 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Stock subscriptions receivable | ||||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| Right-of-use asset, net | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIENCY) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Current lease liability | ||||||||
| Convertible note and accrued interest | ||||||||
| Total current liabilities | ||||||||
| Related party deposit | ||||||||
| Total liabilities | ||||||||
| Series A redeemable convertible preferred stock, par value $. | ||||||||
| STOCKHOLDERS’ EQUITY (DEFICIENCY) | ||||||||
| Authorized preferred stock is | ||||||||
| Series B convertible preferred stocks, par value $ | ||||||||
| Series C convertible preferred stocks, par value $ | ||||||||
| Common stock, par value $.0001. Authorized shares of 135,000,000 and 50,000,000 as of June 30, 2023 and December 31, 2022, respectively. Issued and outstanding shares of 13,099,377 and 3,410,103 as of June 30, 2023 and December 31, 2022, respectively. | ||||||||
| Additional paid in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity (deficiency) | ( | ) | ||||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficiency) | $ | $ | ||||||
The accompanying notes are an integral part of these financial statements.
1
INTENSITY THERAPEUTICS, INC.
Condensed Statements of Operations
(Unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development costs | $ | $ | $ | $ | ||||||||||||
| General and administrative costs | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss on debt conversion | ( | ) | ( | ) | ||||||||||||
| Other | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Loss per share | ||||||||||||||||
| $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||
The accompanying notes are an integral part of these financial statements.
2
Intensity Therapeutics Inc.
Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficiency)
Six Months and Three Months Ended June 30, 2023 and 2022
(unaudited)
| Series
A Redeemable Convertible Preferred Stock | Series
B Convertible Preferred | Series
C Convertible Preferred | Common Stock | Additional Paid in | Accumulated | Stockholders’ Equity | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | (Deficiency) | ||||||||||||||||||||||||||||||||||
| Balances at December 31, 2022 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Stock-based compensation expense | ||||||||||||||||||||||||||||||||||||||||||||
| Warrants issued to convertible note holders | ||||||||||||||||||||||||||||||||||||||||||||
| Warrants issued to underwriters in connection with public offering | ||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in public offering for cash, net of $ | ||||||||||||||||||||||||||||||||||||||||||||
| Issuance of preferred stock for anti-dilution clauses | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
| Conversion of preferred stock into common stock | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Conversion of convertible notes into common stock | ||||||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Balances at June 30, 2023 | $ | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||||
| Balances at March 31, 2023 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Stock-based compensation expense | ||||||||||||||||||||||||||||||||||||||||||||
| Warrants issued to underwriters in connection with public offering | ||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in public offering for cash, net of $ | ||||||||||||||||||||||||||||||||||||||||||||
| Issuance of preferred stock for anti-dilution clauses | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
| Conversion of preferred stock into common stock | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Conversion of convertible notes into common stock | ||||||||||||||||||||||||||||||||||||||||||||
| Net loss | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
| Balances at June 30, 2023 | $ | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||||
| Balances at December 31, 2021 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | ||||||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Balances at June 30, 2022 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Balances at March 31, 2022 | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | ||||||||||||||||||||||||||||||||||||||||||||
| Net loss | $ | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Balances at June 30, 2022 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these financial statements.
3
INTENSITY THERAPEUTICS, INC.
Condensed Statements of Cash Flows
(Unaudited)
| Six Months Ended | ||||||||
| June 30, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Amortization of discount on convertible notes | - | |||||||
| Amortization of right-of-use asset | ||||||||
| Stock-based compensation expense | ||||||||
| Loss on debt conversion | ||||||||
| Changes in operating assets and liabilities, net: | ||||||||
| Other current assets | ( | ) | ||||||
| Accounts payable | ||||||||
| Accrued expenses | ( | ) | ||||||
| Accrued interest on convertible note | ||||||||
| Change in lease liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Net cash provided by investing activities | ||||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from sale of convertible note | ||||||||
| Payout of fractional shares on reverse split | ( | ) | ||||||
| Stock issuance costs on initial public offering | ( | ) | ||||||
| Net cash provided by financing activities | ( | ) | ||||||
| Net decrease in cash and cash equivalents | ( | ) | ( | ) | ||||
| Cash and cash equivalents at beginning of period | ||||||||
| Cash and cash equivalents at end of period | $ | $ | ||||||
| Supplemental disclosure of non-cash operating activities: | ||||||||
| The Company has recorded a Subscription receivable from the sale of | $ | |||||||
| Supplemental disclosure of non-cash financing activities: | ||||||||
| Conversion of convertible notes and accrued interest into common stock | $ | |||||||
| Warrants issued in relation to issuance of convertible notes | $ | |||||||
| Warrants issued to underwriter in connection with stock issuance | $ | |||||||
The accompanying notes are an integral part of these financial statements.
4
INTENSITY THERAPEUTICS, INC.
Notes
to Unaudited Condensed
Financial Statements
Note A — Nature of Business
Intensity Therapeutics, Inc. (“the Company”) is a Connecticut based company that incorporated in Delaware in December 2012. The Company is a biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer. The Company’s DfuseRxSM technology platform has identified a lead drug, INT230-6.
On
April 27, 2023,
As
a result of its initial public offering (“IPO”), the Company began trading on the Nasdaq Capital Market under the symbol
“INTS” on June 30, 2023 and on July 5, 2023 the Company received $
Note B — Liquidity and Plan of Operation
The accompanying unaudited condensed financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern.
The
Company is a development stage company and has not generated any revenue from its product candidates. The Company, therefore, has experienced
net losses and negative cash flows from operations each year since its inception. Through June 30, 2023, the Company has an accumulated
deficit of approximately $
To date, the Company has not obtained regulatory approval for any of its product candidates. The Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability. The Company does not expect to receive significant product revenue in the near term. The Company, therefore, expects to continue to incur substantial losses for the foreseeable future.
Cash
and cash equivalents at June 30, 2023 totaled approximately $
5
INTENSITY THERAPEUTICS, INC.
Notes
to Unaudited Condensed
Financial Statements
Note B — Liquidity and Plan of Operation (continued)
Based on the cash proceeds received in July 2023, the Company expects its cash and cash equivalents to be sufficient to fund operations for a period of 12 months from the date that these financial statements are issued.
Note C — Summary of Significant Accounting Policies and Accounts
[1] Basis of presentation:
The accompanying condensed financial statements include the accounts of Intensity Therapeutics, Inc.
The condensed financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s prospectus filed with the Securities and Exchange Commission on June 29, 2023.
[2] Use of estimates:
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Certain accounting principles require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used.
The Company utilizes significant estimates and assumptions in valuing its stock-based awards. An additional significant estimate is that these financial statements are based on the assumption of the Company continuing as a going concern. See Note B with regard to the Company’s ability to continue as a going concern.
[3] Concentration of credit risk:
The Company’s financial instruments that are exposed to concentrations of credit risk consist entirely of cash. These financial instruments are held at two U.S. financial institutions. The cash accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. During the six months ended June 30, 2023, the Company’s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts. Although the Company believes that the financial institutions with whom the Company does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so beyond amounts guaranteed by the FDIC.
[4] Cash and cash equivalents:
The Company considers all liquid investments with an original maturity of three months or less to be cash equivalents.
6
INTENSITY THERAPEUTICS, INC.
Notes
to Unaudited Condensed
Financial Statements
Note C — Summary of Significant Accounting Policies and Accounts (continued)
[5] Fair value measurement:
The Company reports its investments at fair value. Fair value is an estimate of the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (i.e., the exit price at the measurement date). Fair value measurements are not adjusted for transaction costs. A fair value hierarchy provides for prioritizing inputs to valuation techniques used to measure fair value into three levels:
| Level 1 | Unadjusted quoted prices in active markets for identical assets or liabilities. | |
| Level 2 | Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. | |
| Level 3 | Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability. | |
An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 or Level 2 assets or liabilities.
The Company’s financial instruments, including cash equivalents and current liabilities are carried at cost, which approximates fair value due to the short-term nature of these instruments.
[6] Stock-based compensation:
The Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of Accounting Standards Codification (“ASC”) ASC Topic 718, “Compensation — Stock Compensation”. Stock compensation to employees and non-employees consists of stock option grants that were recognized in the statements of operations based on their fair values at the date of grant.
The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. Forfeitures are recognized as they occur.
[7] Research and development and patent costs:
Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred, due to the uncertainty with respect to future cash flows resulting from the patents and are included as part of general and administrative expenses in the Company’s Statements of Operations.
7
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note C — Summary of Significant Accounting Policies and Accounts (continued)
[8] Income taxes:
The Company accounts for income taxes in accordance with Accounting Standards Codification (ASC) 740, “Income Taxes”. ASC 740 prescribes the use of the asset-and-liability method whereby deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company utilizes a valuation allowance to reduce deferred tax assets to their estimated realizable value.
The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized.
The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At June 30, 2023 the Company does not have any significant uncertain tax positions.
There are no estimated interest costs and penalties provided for in the Company’s financial statements for the six months ended June 30, 2023. If at any time the Company should record interest and penalties in connection with an uncertain tax position, the interest and penalties will be expensed within the income tax line.
The Company’s income tax returns are subject to Federal, state and local income tax examination by the authorities for the last three tax years.
[9] Leases:
The Company determines if an arrangement contains a lease at contract inception. With the exception of short-term leases (leases with terms less than 12 months), all leases with contractual fixed costs are recorded on the balance sheet on the commencement date as a right-of-use (ROU) asset and a lease liability. Lease liabilities to be paid over the next twelve months are classified as current lease liability and all other lease obligations are classified as long-term lease liability. Lease liabilities are initially measured at the present value of the future minimum lease payments and subsequently increased to reflect the interest accrued and reduced by the lease payments made. The Company’s building leases require a pro-rata share of operating expenses and real estate taxes, which are variable in nature and excluded from the measurement of lease liabilities. ROU assets are initially measured at the present value of the future minimum lease payments adjusted for any prior lease pre-payments, lease incentives and initial direct costs. Certain leases contain escalation, renewal and/or termination options that are factored into the ROU asset as appropriate. Operating leases result in a straight-line rent expense over the expected lease term.
The Company uses its estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of future lease payments, if the rate implicit in the lease is not readily determinable. Consideration is given to publicly available data for instruments with similar characteristics when calculating incremental borrowing rates. This incremental borrowing rate estimate is based on a synthetic credit rating derived from the market capitalization of similar companies, the treasury yield curve, and corporate yield spreads.
8
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note C — Summary of Significant Accounting Policies and Accounts (continued)
[10] Basic and dilutive loss per share:
Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Dilutive net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options, and stock warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per share does not include the conversion of securities that would have an anti-dilutive effect. Potential common shares issuable upon conversion of preferred stock, exercise of stock options, and exercise of warrants that are excluded from the computation of diluted weighted average shares outstanding listed in the table below because they are anti-dilutive. The basic and diluted computation of net loss per share for the Company are the same because the effects of the Company’s convertible securities would be anti-dilutive. All common and preferred stock participate equally in dividends and the distribution of earnings if and when declared by the Board of Directors, on the Company’s common stock for the three and six months ended June 30, 2022. For purposes of computing earnings per share, all series of preferred stock are considered participating securities. Therefore, the Company must calculate basic and diluted earnings per share using the two-class method. Under the two-class method, net income for the period is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed earnings. As the preferred shareholders have no obligation to fund losses no portion of net loss was allocated to the participating securities for the three months or six months ended June 30, 2022. There were no preferred shares outstanding at June 30, 2023.
At
June 30, 2023 and 2022,
| June 30, | June 30, | |||||||
| 2023 | 2022 | |||||||
| Preferred stock Series A outstanding | ||||||||
| Preferred stock Series B outstanding | ||||||||
| Preferred stock Series C outstanding | ||||||||
| Options outstanding | ||||||||
| Warrants outstanding | ||||||||
As of June 30, 2022 the shares that would be issued from the convertible notes outstanding are also excluded from diluted weighted average shares outstanding, since the conversion rate is dependent upon qualified liquidity events. All convertible notes were converted into common shares prior to June 30, 2023.
[11] Recently issued pronouncements:
The Company does not believe that any recently issued, but not yet effective, accounting pronouncements,
if currently adopted, would have a material impact on its financial statements.
[12] Reclassifications:
Certain prior year amounts have been reclassified to conform to current year presentation.
9
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note D — Other Current Assets
| June
30, 2023 | December
31, 2022 | |||||||
| Prepaid insurance | $ | $ | ||||||
| Prepaid rent | ||||||||
| Advances to vendors | ||||||||
| Tax credit receivable | ||||||||
| Receivable with related party | ||||||||
| Other current assets | ||||||||
| $ | $ | |||||||
Note E — Other Assets
| June
30, 2023 | December
31, 2022 | |||||||
| Deposit with vendor | $ | $ | ||||||
| Deposit with landlord | ||||||||
| $ | $ | |||||||
Note F — Accrued Expenses
| June
30, 2023 | December
31, 2022 | |||||||
| Accrued vacation, wages, and related payroll taxes | $ | $ | ||||||
| Patient costs incurred but not yet invoiced | ||||||||
| Accrued other | ||||||||
| $ | $ | |||||||
10
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note G — Convertible Notes
On
September 20, 2021, the Company entered into a convertible debt agreement (the “2021 Convertible Note”) with a shareholder
for aggregate principal of $
On
November 21, 2022, the Company entered into two convertible debt agreements (the “November 21, 2022 Convertible Notes”) with
shareholders for $
On
November 29, 2022, the Company entered into a convertible debt agreement (the “November 29, 2022 Convertible Note”) for $
11
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note G — Convertible Notes (continued)
On
March 16, 2023, the Company entered into a convertible debt agreement (the “March 16, 2023 Convertible Note”) for $
On
April 1, 2023, the Company entered into a convertible debt agreement (the “April 1, 2023 Convertible Note”) for $
On
May 11, 2023, the Company entered into a convertible debt agreement (the “May 11, 2023 Convertible Note”) for $
All
of the convertible notes had a contingent beneficial conversion feature. The value of this beneficial conversion feature had not yet
been determined at December 31, 2022 since an IPO price had not been determined or an equity event had not occurred. A loss of $
12
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note G — Convertible Notes (continued)
| Principal | Accrued Interest | Total | ||||||||||
| Convertible note dated September 20, 2021 | $ | $ | $ | |||||||||
| Convertible notes dated November 21, 2022 | ||||||||||||
| Convertible note dated November 29, 2022 | ||||||||||||
| $ | $ | $ | ||||||||||
There
was no balance in Convertible notes as of June 30, 2023 since all principal and accrued interest of $
At
December 31, 2022 the Company classified the convertible notes as a current liability since the Company anticipated that these notes
will automatically convert into common shares within one year of the balance sheet date. The unamortized discount was amortized over
the life of the convertible notes. The unamortized balance at the time of the conversion into common shares of approximately $
Note H — Stockholders’ Equity
On
June 29, 2023, as described in Note A, the Company had it’s IPO. At the time of the IPO, all preferred stock was converted into
common shares at conversion prices that reflected the reverse split. All convertible notes and related accrued interest were converted
into common stock, as described in Note G. The Company issued an additional
Note I — Common Stock Warrants
| Number
of Shares Underlying Warrants | Weighted Average Exercise Price | |||||||
| Outstanding at January 1, 2022 | $ | |||||||
| Issued | ||||||||
| Forfeited | ||||||||
| Outstanding March 31, 2022 | ||||||||
| Issued | ||||||||
| Forfeited | ||||||||
| Outstanding June 30, 2022 | $ | |||||||
| Outstanding January 1, 2023 | $ | |||||||
| Issued | ||||||||
| Forfeited | ||||||||
| Outstanding March 31, 2023 | ||||||||
| Issued | ||||||||
| Forfeited | ||||||||
| Outstanding June 30, 2023 | $ | |||||||
| Exercisable June 30, 2023 | $ | |||||||
13
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note I — Common Stock Warrants (continued)
| Stock price | $ | |||
| Exercise price | $ | |||
| Expected volatility | % | |||
| Risk free interest rates | % | |||
| Expected term |
The following table summarizes the assumptions used to estimate the fair value of stock warrants granted on June 30, 2023 as part of the IPO:
| Stock price | $ | |||
| Exercise price | $ | |||
| Expected volatility | % | |||
| Risk free interest rates | % | |||
| Expected term |
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Research and Development | $ | $ | $ | $ | ||||||||||||
| General and Administrative | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
At
June 30, 2023, total unrecognized compensation cost related to warrants was approximately $
The
aggregate intrinsic value of outstanding warrants is calculated as the difference between the exercise price of the stock warrants and
the fair value of the Company’s common stock for those stock warrants that had exercise prices lower than the fair value of the
Company’s common stock. The aggregate intrinsic value of outstanding warrants was approximately $
14
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note J — Stock Based Compensation
The
Company had a stock option plan, the 2013 Plan, which is administered by the Committee. Under the 2013 Plan, stock options to purchase
a total of
In
2020, the Company amended its 2013 Stock Option Plan (the “2013 Plan”) to increase the number of authorized shares available
under the 2013 Plan from
| Number
of Shares Underlying Options | Weighted Average Exercise Price | |||||||
| Outstanding at January 1, 2022 | $ | |||||||
| Issued | ||||||||
| Forfeited | ||||||||
| Outstanding March 31, 2022 | ||||||||
| Issued | ||||||||
| Forfeited | ||||||||
| Outstanding June 30, 2022 | $ | |||||||
| Outstanding January 1, 2023 | $ | |||||||
| Issued | ||||||||
| Forfeited | ||||||||
| Outstanding March 31, 2023 | ||||||||
| Issued | ||||||||
| Forfeited | ||||||||
| Outstanding June 30, 2023 | $ | |||||||
| Exercisable June 30, 2023 | $ | |||||||
The
aggregate intrinsic value of outstanding options is calculated as the difference between the exercise price of the stock options and
the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the
Company’s common stock. The aggregate intrinsic value of options outstanding was approximately $
Employee option vesting is based on the employee’s continued service with the Company.
The 2013 Plan and the 2021 Plan provide an immediate vesting of outstanding options in the event of a change of control, such as an acquisition, notwithstanding any other provision of the 2013 Plan or 2021 Plan.
15
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note J — Stock Based Compensation (continued)
There were no stock options issued during the six months ended June 30, 2023 and 2022.
At
June 30, 2023, total unrecognized compensation cost related to options was approximately $
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Research and Development | $ | $ | $ | $ | ||||||||||||
| General and Administrative | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
All
options expire
Note K — Leases
In
January 2017, the Company entered into a lease for
In
July 2020, the Company amended this lease to increase office space by an additional
| Year 1 (October 2020 through September 2021) | ||
| Year 2 (October 2021 through September 2022) | ||
| Year 3 (October 2022 through September 2023) |
The Company has an option to extend this amended lease for an additional 3 years at the following amounts:
| Year 4: (October 2023 through September 2024) | ||
| Year 5: (October 2024 through September 2025) | ||
| Year 6: (October 2025 through September 2026) |
16
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note K — Leases (continued)
The Company had until March 31, 2023 to exercise this option to extend. On February 27, 2023, the Company informed the landlord that it will not exercise its option to extend the amended lease. On March 27, 2023, the Company modified the lease to reduce the office space as of April 30, 2023 and to further reduce the office space as of May 31, 2023. These two modifications reduced the operating lease asset and liability. The amended lease was set to expire on September 30, 2023. On April 17, 2023 another modification was made to the lease that terminated the lease as of June 30, 2023.
The
Company also pays a pro-rata share of operating expenses and real estate taxes. The following variables were used to determine the right-of-use
asset and the operating lease liabilities as of commencement date: Weighted average remaining lease term
On
July 7, 2023 the Company signed a
| 2023 | 2022 | |||||||
| Operating lease right-of-use assets | $ | $ | ||||||
| Current portion of operating lease liabilities | $ | $ | ||||||
| Long-term operating lease liabilities | ||||||||
| $ | $ | |||||||
There are no future rental payments under operating leases as of June 30, 2023.
Note L — Other Uncertainties
The Company holds one of its patents in Russia. The payment for this patent is paid until September 15, 2024. If subsequent payments to Russia are restricted, the Company may lose this patent in Russia. The Company has no other significant business activities in Belarus, Russia or the Ukraine.
17
INTENSITY THERAPEUTICS, INC.
Notes to Unaudited Condensed
Financial Statements
Note M — Related Parties
At
June 30, 2023 and December 31, 2022, the Company was holding a $
In
February 2022, a minority stockholder became a consultant to the Company. Services provided include acting as the Company’s Chief
Medical Officer. Although the terms of this agreement have not been finalized, the Company has accrued approximately $
Sublease
income from the related party was approximately $
Note N — Income Taxes
The
Company recorded Federal research & development credits, of approximately $
The
Net operating loss generated for the six months ended June 30, 2023 was approximately $
At
June 30, 2023, aside from the Federal research and development tax credits used to offset Social Security taxes, the Company had Federal
General Business Credit carryforwards of approximately $
At
June 30, 2023, the Company has Connecticut research and development tax credit carryforwards of approximately $
Note O — Retirement Plan – Defined Contribution
The
Company maintains a defined contribution plan for all employees age 21 and older who have completed one month of service. This 401K plan
began for payrolls after July 1, 2017. The Company makes a matching contribution equal to
18
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may include statements concerning, among other things, our business strategy (including anticipated trends and developments in, and management plans for, our business and the markets in which we operate), financial results, operations, and the markets and communities in which we, our clients, and partners operate, results of operations, revenues, operating expenses, and capital expenditures, sales and marketing initiatives and competition. In some cases, you can identify forward-looking statements because they contain words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “suggests,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These statements are not guarantees of future performance; they reflect our current views with respect to future events and are based on assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from expectations or results projected or implied by forward-looking statements.
We discuss many of these risks in our Final Prospectus on Form 424(b)(4) dated June 29, 2023, in greater detail under the heading “Risk Factors” and in other filings we make from time to time with the Securities and Exchange Commission (“SEC”). Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q, which are inherently subject to change and involve risks and uncertainties. Unless required by federal securities laws, we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated, to reflect circumstances or events that occur after the statements are made. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors. Such factors include, but are not limited to, the following:
| ● | the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs; |
| ● | our need to raise additional funding before we can expect to generate any revenues from product sales; |
| ● | our plans to develop and commercialize our product candidates; |
| ● | the timing or likelihood of regulatory filings and approvals; |
| ● | the ability of our research to generate and advance additional product candidates; |
| ● | the implementation of our business model, strategic plans for our business, product candidates and technology; |
| ● | our commercialization, marketing and manufacturing capabilities and strategy; |
| ● | the rate and degree of market acceptance and clinical utility of our system; |
| ● | our competitive position; |
| ● | our intellectual property position; |
| ● | developments and projections relating to our competitors and our industry; |
| ● | our ability to maintain and establish collaborations or obtain additional funding; and |
| ● | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. |
You should read this Quarterly Report on Form 10-Q and the documents that we reference in this report and have filed with the SEC, including our Final Prospectus on Form 424(b)(4) dated June 29, 2023, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
References to “Notes” are notes included in our unaudited Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Unless otherwise indicated, the terms “Intensity,” “Company,” “we,” “us,” or “our” refer to Intensity Therapeutics, Inc.
19
Overview
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform.
The concept of intratumoral treatment (IT) has been an objective of clinicians since the first discovery of chemotherapeutic agents. Keeping the drug in the tumor and sparing the body of toxicity. The challenge with IT treatment approaches is that a tumor’s lipophilic, high fat and pressurized microenvironment is incompatible with and does not absorb water-based products. We believe that intratumoral drug delivery is a chemistry challenge and that prior or current IT treatments have formulated their product without consideration of the compatibility of water and tumors. Another issue with IT or local delivery has been that metastatic cancer is mostly a whole body disease. Local treatments need a systemic component to be effective for a survival benefit. Accordingly, there remains a continued unmet need for the development of direct IT therapies for solid tumors that provide high local killing efficacy coupled with nontoxic systemic anti-cancer effects. We believe we have created such a product candidate with the necessary chemistry to overcome this local delivery challenge and a mechanism of action that induces a systemic effect. Clinical and nonclinical evidence shows that our drug candidate’s mechanism of tumor killing also leads to immune activation in certain cancers.
Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have two distinct components: one part is soluble in water and the other is soluble in fat or oils. When certain amphiphilic compounds are mixed with therapeutic agents, such as chemotherapies, the agents can also become soluble in both fat and water. Our product candidates include novel formulations consisting of potent anti-cancer drugs mixed together with these amphiphilic agents.
Our lead product candidate, INT230-6, consists of two proven anti-cancer cytotoxic agents, cisplatin and vinblastine sulfate, mixed with the amphiphilic molecule (SHAO) — all in one vial. The anti-cancer agents, cisplatin and vinblastine sulfate, used in our product candidate are both generic. These agents are available to purchase in bulk supply commercially. In 2017, we initiated a Phase 1/2 dose escalation study using INT230-6 in the United States under an investigational new drug application (“IND”) authorized by the FDA and in Canada following receipt of a no objection letter from Health Canada. The study, IT-01, explored the safety and efficacy of INT230-6 in patients with refractory or metastatic cancers. We completed enrollment of study IT-01 in June 2022 and locked the IT-01 database in February 2023.
Our first clinical trial dosed 110 patients. This clinical trial used our lead product candidate INT230-6 alone; in combination with Merck’s Keytruda (pembrolizumab) for patients with advanced solid malignancies including pancreatic, bile duct, squamous cell, and non-MSI high colon cancers; and in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) for patients with breast cancer, liver cancer, and advanced sarcoma.
Our second clinical trial (the INVINCIBLE Study or IT-02) tested INT230-6 in early stage breast cancer for patients not suitable for presurgical chemotherapy. The study enrolled 91 subjects; enrollment is now complete. This clinical trial was a Phase 2 randomized, window of opportunity for patients who were ineligible or chose not to have presurgical chemotherapy. The key endpoint was whether INT230-6 could reduce patient’s cancer by 50% to 100% defined as a major pathological response compared to no treatment (the current standard of care) or a saline injection and stimulate a systemic anti-cancer immune response prior to surgery. Substantial reduction of cancer presurgically in aggressive forms of cancer has been shown to correlate with delaying disease recurrence. Other endpoints of the INVINCIBLE study were to understand the percentage of necrosis that can be achieved in tumors especially tumors larger than 2 cm in longest diameter and whether an anti-cancer immune response could be induced.
Since our inception in 2012, our operations have included business planning, hiring personnel, raising capital, building our intellectual property portfolio, and performing both research and development on our product candidates. We have incurred net losses since inception and expect to incur net losses in the future as we continue our research and development activities. To date, we have funded our operations primarily through approximately $50.7 million from the net proceeds of sales of our common stock, preferred stock and convertible notes. As of June 30, 2023, we had approximately $136,000 of cash and cash equivalents, and received approximately $17.8 million in cash, net of costs, on July 5, 2023 from the proceeds of our Initial Public Offering (“IPO”) plus approximately $2.7 million in cash, net of costs, on July 7, 2023 from the proceeds from the underwriters’ full exercise of its overallotment option of IPO shares. These two cash receipts total approximately $20.5 million. Since our inception, we have incurred significant operating losses. We incurred net losses of $3.7 million and $1.9 million for the three months ended June 30, 2023 and 2022, respectively, and losses of $5.0 million and $4.3 million for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, we had an accumulated deficit of approximately $43.7 million. We expect to incur significant expenses and operating losses for the next several years. See “Funding Requirements” below.
We expect our expenses to increase as we continue to:
| ● | Initiate Phase 3 programs in sarcoma and/or breast cancer; |
| ● | Complete our current Phase 2 programs; |
| ● | Advance our preclinical research and bring new product into clinical development; |
| ● | Incur manufacturing costs for additional GMP batches of our product candidates and enhancer molecules; |
| ● | Seek regulatory approvals for any of our product candidates that successfully complete clinical trials; |
| ● | Hire additional personnel; |
20
| ● | Expand our operational, financial, and management systems; |
| ● | Invest in measures to protect our existing and new intellectual property; and |
| ● | Establish a sales, marketing, medical affairs, and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize. |
Our ability to ultimately generate revenue to achieve profitability will depend heavily on the development, approval, and subsequent commercialization of our product candidates. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financing, or other capital sources, which may include collaborations with other companies or other strategic transactions. We may not be able to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we would have to significantly delay, reduce, or eliminate the development and commercialization of one or more of our product candidates.
Components of Results of Operations
Revenue
To date, we have not generated any revenue from product sales and we do not expect any revenue from the sale of product in the foreseeable future. We have not generated any revenue from licensing of our technology or product candidates yet either. If our development efforts for any of our product candidates are successful and result in regulatory approval, then we may generate revenue in the future from product sales or licensing. We cannot predict if, when, or to what extent we will generate revenue from the commercialization, licensing or sale of any of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.
Research and Development Costs
Salaries and Payroll Taxes
Salaries and payroll taxes include Company employees involved in our pre-clinical research and clinical trials. This includes medical officers, project management, manufacturing staff and research scientists. The payroll taxes include all government required payments such as social security and unemployment taxes.
Fringe Benefits
We offer a partially funded health insurance and dental insurance plan. We maintain a defined contribution plan for all employees age 21 and older who have completed one year of service. This 401K plan makes a matching contribution equal to 100% of an employee’s contribution, up to 3% of an employee’s eligible earnings.
Research Costs
Research costs include:
| ● | Pre-clinical research |
| ● | Manufacture of new enhancer compounds, |
| ● | Manufacture and labelling of GMP product candidate |
| ● | Product candidate stability testing of GMP batches |
| ● | Costs due to clinical trials for patient care |
| ● | Other clinical trial costs such as shipping, storage, and analytical testing |
Scientific Consulting
Scientific consulting is costs related to non-employees involved in research. This category includes: statistical analysis, clinical trial operations, development of product manufacturing techniques, and internet research related to oncology and chemistry issues that may impact our preclinical or clinical research.
Stock-Based Compensation
Stock-based compensation is the expense related to stock options granted to our employees and warrants granted to our independent consultants who work in the research aspects.
21
General and Administrative Costs
Salaries and Payroll Taxes
Salaries and payroll taxes includes Company employees who are involved in fund raising, management, and our financial administration. The payroll taxes include all government required payments such as social security and unemployment taxes.
Fringe Benefits
We offer a partially funded health insurance and dental insurance plan. We maintain a defined contribution plan for all employees age 21 and older who have completed one year of service. This 401K plan makes a matching contribution equal to 100% of an employee’s contribution, up to 3% of an employee’s eligible earnings.
Legal
Legal costs relate primarily to our corporate administration. All legal costs relate to expenses for outside corporate law firms.
Patent and Trademark
Patent and Trademark are the legal costs and filing costs to establish and maintain patents in 38 countries.
Insurance
Insurance includes: directors and officers insurance, workers compensation insurance, product liability insurance, business insurance, employee and cyber liability insurance.
Facilities and Rent
Facilities and rent is the cost of maintaining our office facility in Westport, Connecticut through June 30, 2023. In July 2023, we signed a lease to move into 2,686 square feet of office space at 1 Enterprise Drive, Suite 430, Shelton, Connecticut to improve recruiting of staff and to reduce costs. The initial base rent payments are zero for the first six months, $2,910 for the next six months, and gradually increase to $3,275 per month for the last twelve months of the lease. The Company has an option to cancel this lease after 36 months. Additional monthly variable charges for electricity and common charges per month will be incurred.
Investor Relations
Investor relations are costs paid to outside consultants to develop the materials to present to prospective investors, and to arrange meetings with potential investors.
Accounting Services
Accounting services include the cost of our independent auditors for our annual audit, quarterly reviews, and services related to the filing of our registration statement on Form S-1, which was declared effective on June 29, 2023. This category also includes costs related to the preparation of income tax returns, and the cost of maintaining our accounting system. Accounting services on our IPO were not included in this category. The costs related to the IPO were recorded as a reduction of proceeds of the offering and are part of additional paid in capital.
Other
Other general and administrative costs include such items as office supplies, computer related costs, public relations costs, recruiting costs and conferences.
Stock-Based Compensation
Stock-based compensation is the expense related to stock options granted to our employees and warrants granted to our independent consultants who work in the general and administrative aspects.
Other income and expenses
We earned interest income on our cash balances.
We incurred interest expense on our convertible notes. Accrued interest was converted into common stock upon completion of our IPO.
22
We received Federal Research and Development tax credits that are recoverable through a refund of Social Security taxes paid by the Company.
Results of Operations
The following table summarizes our results of operations for the six months and three months ended June 30, 2023 and 2022 (in thousands):
| Six
Months Ended June 30, | Increase | Three Months Ended
June 30 | Increase | |||||||||||||||||||||
| 2023 | 2022 | (Decrease) | 2023 | 2022 | (Decrease) | |||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||
| Research and development costs | $ | 1,633 | $ | 3,080 | $ | (1,447 | ) | $ | 859 | $ | 1,385 | $ | (526 | ) | ||||||||||
| General and administrative costs | 843 | 1,229 | (386 | ) | 363 | 545 | (182 | ) | ||||||||||||||||
| Total operating costs | 2,476 | 4,309 | (1,833 | ) | 1,222 | 1,930 | (708 | ) | ||||||||||||||||
| Loss from operations | (2,476 | ) | (4,309 | ) | 1,833 | (1,222 | ) | (1,930 | ) | 708 | ||||||||||||||
| Other income (expense) | (2,561 | ) | 12 | (2,573 | ) | (2,479 | ) | 2 | (2,481 | ) | ||||||||||||||
| Net loss | $ | (5,037 | ) | $ | (4,297 | ) | $ | (740 | ) | $ | (3,701 | ) | $ | (1,928 | ) | $ | (1,773 | ) | ||||||
| Loss per share, basic and diluted common | $ | (1.45 | ) | $ | (1.26 | ) | $ | (1.05 | ) | $ | (0.57 | ) | ||||||||||||
| Weighted average number of common stock, basic and diluted | 3,463,635 | 3,410,103 | 3,516,579 | 3,410,103 | ||||||||||||||||||||
| Six
Months Ended June 30, | Increase | Three Months
Ended June 30, | Increase | |||||||||||||||||||||
| 2023 | 2022 | (Decrease) | 2023 | 2022 | (Decrease) | |||||||||||||||||||
| Research and development costs by expense type: | ||||||||||||||||||||||||
| Salaries and payroll taxes | $ | 280 | $ | 668 | $ | (388 | ) | $ | 125 | $ | 271 | $ | (146 | ) | ||||||||||
| Benefits | 49 | 105 | (56 | ) | 24 | 50 | (26 | ) | ||||||||||||||||
| Stock based compensation | 465 | 314 | 151 | 230 | 155 | 75 | ||||||||||||||||||
| Clinical trial costs | 839 | 1,993 | (1,154 | ) | 480 | 909 | (429 | ) | ||||||||||||||||
| $ | 1,633 | $ | 3,080 | $ | (1,447 | ) | $ | 859 | $ | 1,385 | $ | (526 | ) | |||||||||||
23
| Six
Months Ended June 30, | Three Months
Ended June 30, | |||||||||||||||||||||||
| 2023 | 2022 | Increase/ Decrease | 2023 | 2022 | Increase/ Decrease | |||||||||||||||||||
| General and administrative costs: | ||||||||||||||||||||||||
| Salaries and payroll taxes | $ | 170 | $ | 157 | $ | 13 | $ | 81 | $ | 77 | $ | 4 | ||||||||||||
| Fringe benefits | 8 | 11 | (3 | ) | 4 | 5 | (1 | ) | ||||||||||||||||
| Legal | 141 | 259 | (118 | ) | 44 | 133 | (89 | ) | ||||||||||||||||
| Patent and trademark | 33 | 25 | 8 | 14 | - | 14 | ||||||||||||||||||
| Insurance | 34 | 41 | (7 | ) | 19 | 19 | - | |||||||||||||||||
| Facilities and rent | 67 | 72 | (5 | ) | 28 | 37 | (9 | ) | ||||||||||||||||
| Investor relations | 67 | 100 | (33 | ) | 33 | 34 | (1 | ) | ||||||||||||||||
| Accounting services | 88 | 176 | (88 | ) | 16 | 76 | (60 | ) | ||||||||||||||||
| Consulting services | 35 | 121 | (86 | ) | 22 | 58 | (36 | ) | ||||||||||||||||
| Other | 41 | 80 | (39 | ) | 20 | 37 | (17 | ) | ||||||||||||||||
| Stock-based compensation | 159 | 187 | (28 | ) | 82 | 69 | 13 | |||||||||||||||||
| $ | 843 | $ | 1,229 | $ | (386 | ) | $ | 363 | $ | 545 | $ | (182 | ) | |||||||||||
Six Months Ended June 30, 2023 Compared to Six Months Ended June 30, 2022
Research and Development expenses decreased by 47.0% as studies IT-01 and IT-02 completed their enrollments in June 2022 and August 2022 respectively. During the six months ended June 30, 2023, we engaged clinical and regulatory consultants to replace positions occupied by full time staff required during the recruiting phases of the trials. Dr. Walters moved to a consulting role with reduced hours and costs. Our IT-03 Phase 3 study continued to move forward in design and protocol drafting in 2022. Our IT-01 study continued to generate data; however, costs to close out the study were incurred in lieu of patient related treatment expenses.
General and Administrative expenses decreased from approximately $1.2 million to approximately $0.8 million. The decrease in General and Administrative and Accounting services was due to the preparations for an IPO in the six months ended June 30, 2022. The accounting and legal costs related to the IPO in 2023 were charged directly to the equity section of the balance sheet as a reduction of additional paid in capital.
Other income (expense) is primarily the approximately $2.3 million loss related to the discount given to convertible note holders when their convertible notes and accrued interest converted to shares of common stock at discounts of 30 or 35%,
Three Months Ended June 30, 2023 Compared to Three Months Ended June 30, 2022
Research and Development expense decreased by 38.0% since Study IT-01 and Study IT-02 no longer have patient care costs and the drafting of results is nearly complete. Phase 3 IT-03 in sarcoma and phase 2/3 IT-04 in presurgical breast cancer will continue to incur planning, multiple regulatory filing, manufacturing, study initiation and trial preparation costs in 2023.
General and Administrative expenses decreased from approximately $545,000 to $363,000 primarily due to 2022 having the costs of delaying the IPO. The accounting services and legal costs related to the IPO in 2023 were charged directly to the equity section of the balance sheet as a reduction of additional paid in capital.
24
Liquidity and Capital Resources
Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our product candidates. We expect that our research and development and general and administrative costs will continue to increase significantly, including in connection with conducting clinical trials for our product candidates, developing our manufacturing capabilities and building and qualifying our manufacturing facility to support clinical trials and commercialization and providing general and administrative support for our operations, including the cost associated with operating as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources.
We do not currently have any approved products and have never generated any revenue from product sales. We have financed our operations primarily through an initial investment from our founder, the issuance and sale of convertible debt notes, the issuance and sale of private equity financings, and an IPO that began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “INTS” on June 30, 2023. As of June 30, 2023, our cash and cash equivalents were approximately $136,000, and the net IPO cash proceeds received on July 5, 2023 was approximately $17.8 million. On July 7, 2023, we received an additional $2.7 million (approximately) in net cash proceeds from the sale of the underwriters’ full exercise of its overallotment option, which occurred after the IPO. The total net cash proceeds received following the closing of the IPO, therefore, was approximately $20.5 million. Based on these subsequent cash receipts, we project to have sufficient cash to fund our current operating plan until July 2025.
The following table summarizes the net cash provided by (used for) operating activities, investing activities and financing activities for the periods indicated (in thousands):
| Six Months
Ended June 30, | ||||||||
| 2023 | 2022 | |||||||
| Net cash (used in) operating activities | $ | (1,139 | ) | $ | (2,817 | ) | ||
| Net cash (used in) financing activities | (37 | ) | - | |||||
| Net (decrease) in cash and cash equivalents | $ | (1,176 | ) | $ | (2,817 | ) | ||
Operating Activities
Net cash used in operating activities for the six months ended June 30, 2023 was a deficit of approximately $1.1 million. This is primarily attributable to the loss of $5.0 million and the addback of $2.3 million for the non-cash loss on the conversion of convertible notes into shares of common stock and the addback of $0.6 million for the non-cash stock based compensation.
Net cash used in operating activities for the six months ended June 30, 2022 was predominantly the approximately $4.3 million loss that was offset by approximately $0.5 million of non-cash stock based compensation.
Investing Activities
There was no cash provided by or used in investing activities in any of the periods listed above.
Financing Activities
Net cash provided by financing activities for the six months ended June 30, 2023 consisted of the receipt of approximately $0.2 million in convertible notes which was offset by approximately $0.2 million in stock issuance costs related to the IPO. There was no net cash provided by financing activities for the six months ended June 30, 2022. The cash proceeds from the IPO will be recorded in the fiscal period subsequent to June 30, 2023.
Seasonality
Our business experiences limited seasonality.
25
Contractual Obligations, Commitments and Contingencies
As of June 30, 2023, we had no contractual obligations for leases. Our office lease in Wesport, Connecticut terminated on June 30, 2023. On July 7, 2023, we signed a lease for 2,686 square feet of office space in Shelton, Connecticut. The lease term is 66 months, but we have an option to terminate this lease after 36 months.
JOBS Act Accounting Election
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company”, we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our IPO or until we are no longer an “emerging growth company,” whichever is earlier.
Critical Accounting Policies and Estimates
Our management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may materially differ from these estimates under different assumptions or conditions.
While our significant accounting policies are described in more detail in the notes to our financial statements included elsewhere in this report, we believe that the following accounting policies are those most significant to the judgments and estimates used in the preparation of our consolidated financial statements.
Accrued Research and Development Expenses
Research and development costs are expensed as incurred. We record the estimated patient care costs as services are provided but not yet invoiced and include these costs in the accrued expenses in the balance sheet and within research other expense in the statement or operations.
Equity-Based Compensation
We recognize compensation costs related to stock option grants to employees and board members and warrant grants to nonemployees based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value and the resulting stock-based compensation expense using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is recognized on a straight-line basis over the requisite service periods, which are generally the vesting period of the respective awards. Forfeitures are accounted for as they occur.
We historically have been a private company and lack company-specific historical and implied volatility information for our shares. Therefore, we estimate our expected share price volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded share price.
26
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable.
Item 4. Controls and Procedures.
Historically, as a privately held company, we have maintained internal controls over financial reporting but we have a material weakness due to a lack of segregation of duties since we have a limited administrative staff. However, these internal controls have not been subject to the testing required under the standards of publicly traded companies by Section 404 of Sarbanes-Oxley. We are not currently required to comply with SEC rules that implement Sections 302 and 404 of the Sarbanes-Oxley Act, and are therefore not required to make a formal assessment of the effectiveness of our internal controls over financial reporting for that purpose. However, at such time as Section 302 of the Sarbanes-Oxley Act is applicable to us, we will be required to evaluate our internal controls over financial reporting.
Evaluation of Disclosure Controls and Procedures: We maintain disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that the information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and such information is accumulated and communicated to management, including the Chief Executive Officer, Executive Vice President of Corporate Finance and the Interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurances of achieving the desired controls.
As of June 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including the Chief Executive Officer, Executive Vice President of Corporate Finance and the Interim Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures defined above. Based upon that evaluation, our Chief Executive Officer, Executive Vice President of Corporate Finance and Interim Chief Financial Officer have concluded that, as of June 30, 2023, our disclosure controls and procedures were not effective at the reasonable assurance level. In June 2023, the Company appointed an Interim Chief Financial Officer and Executive Vice President of Corporate Finance, but there continues to be a lack of segregation of duties due to a limited number of administrative employees and consultants resulting in a material weakness in internal controls.
Limitations on the Effectiveness of Controls. Our management, including the Chief Executive Officer, Executive Vice President, Corporate Finance and the Chief Financial Officer, recognizes that any set of controls and procedures, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with us have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. For these reasons, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. This lack of segregation of duties from a limited number of administrative employees is a material weakness in internal controls. In August 2021, the Company established a Chief Financial Officer position through a consulting agreement with Danforth Advisors’ James Ahlers in order to add an additional layer of oversight on the financial reporting process with assistance from another Danforth consultant, Norman Staskey, and to address this material weakness. In June 2023, to meet listing requirements of Nasdaq, our Principal Accounting Officer and Controller, John Wesolowski, became our full-time Interim Chief Financial Officer and James Ahlers became our Executive Vice President of Corporate Finance.
27
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we are made aware of legal allegations arising in the ordinary course of our business. We are not currently a party to any actions, claims, suits or other legal proceedings the outcome of which, if determined adversely to Intensity, would individually or taken together have a material adverse effect on our business, operating results, cash flows or financial condition.
Item 1A. Risk Factors
There have not been any material changes to the information related to the “Risk Factors” disclosure in the Company’s Final Prospectus on Form 424(b)(4) dated June 29, 2023. Our business involves significant risks. You should carefully consider the risks and uncertainties described in our Final Prospectus, together with all of the other information in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Final Prospectus. The risks and uncertainties described in our Annual Report are not the only ones we face.
Additional risk and uncertainties that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. The realization of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of operations, growth and future prospects as well as our ability to accomplish our strategic objectives. In that event, the market price of our common stock could decline and you could lose part or all of your investment.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On April 1, 2023, the Company entered into a convertible debt agreement with its landlord for aggregate principal of $12,552. The outstanding principal balance together with the unpaid and accrued interest of the notes was converted upon the completion of the Company’s IPO at a conversion price equal to 70% of its initial public offering price, for a total of 3,631 shares of common stock.
On May 11, 2023, the Company entered into a convertible debt agreement with a holder for aggregate principal of $25,000. The outstanding principal balance together with the unpaid and accrued interest of the notes was converted upon the completion of the Company’s IPO at a conversion price equal to 70% of its initial public offering price, for a total of 7,228 shares of common stock.
On June 29, 2023, our Registration Statement on Form S-1, as amended (File No. 333-260565), was declared effective in connection with our IPO, pursuant to which we sold an aggregate of 3,900,000 shares of common stock to The Benchmark Company, LLC, as representative of the underwriters (the “Representative”), at a public offering price of $5.00 per share for total gross proceeds of $19,500,000. On July 10, 2023, we sold an additional 585,000 shares of common stock to the Representative in connection with its exercise in full of its over-allotment option at a public offering price of $5.00 per share for additional gross proceeds of $2,925,000. The Company intends to use the proceeds primarily to (i) initiate and conduct studies related to its therapeutic treatments, (ii) conduct clinical trials and operations, (iii) develop its product candidates, and (iv) fund its working capital and general corporate activities.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
28
Item 6. Exhibits
| * | Filed herewith. |
29
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INTENSITY THERAPEUTICS, INC. | ||
| By: | /s/ Lewis H. Bender | |
| Lewis H. Bender | ||
| President and Chief Executive Officer | ||
| (principal executive officer) | ||
| Date: August 14, 2023 | ||
| By: | /s/ John Wesolowski | |
| John Wesolowski | ||
| Interim Chief Financial Officer, Principal Accounting Officer and Controller | ||
| (principal financial and accounting officer) | ||
| Date: August 14, 2023 | ||
30